Efficacy of Social Cognitive Training (SCT) in Recent-onset Psychosis

January 8, 2020 updated by: Lana Kambeitz-Ilankovic, Ludwig-Maximilians - University of Munich

Elucidating the Efficacy and Response to Social Cognitive Training (SCT) in Recent Onset Psychosis (ROP)

Participants with recent onset psychosis (ROP) experience delusions, hallucinations, and impairment in social, cognitive and emotional functioning. Although symptoms often improve following pharmacological intervention, the marked cognitive deficits, that often precede the onset of symptoms, continue to persist despite current treatment methods. Computerized neurocognitive interventions (NCI) are a promising therapeutic approach in participants with chronic schizophrenia and individuals at risk for psychosis. Specifically, focus has shifted to social cognitive training (SCT) as treating social cognition have been shown to provide improvements not only in general cognitive deficits but is also related to improvements in functional outcome (occupational and social). NCIs include non-invasive computerized tasks that are done on a tablet. This intervention can be conducted in a clinical setting, as well as out of the comfort of one's home. Additionally, research has shown that NCIs have the potential to elicit neuroplastic effects on the brain.

The purpose of this study is to explore the efficacy of a 10-hour SCT in improving the primary outcome measure, global cognition, and secondary outcome measure, global functioning, in ROP participants. It is hypothesized that participants receiving the intervention will show gains in global cognition, as well as the subdomains of social cognition, processing speed, and working memory. Additionally, participants undergoing active intervention are expected to show gains in functional connectivity primarily between the prefrontal cortex and amygdala and other brain areas, that are engaged in social cognition.

Furthermore, machine learning approach will be used(support vector classification) to investigate how the decision scores of the resting state classifier, indicating health vs. disease proneness, change in response to the training.

In this randomized controlled trial, participants with a ROP receive a 4-6-week treatment with 10 hours of SCT, with 30-minute sessions 4-5 times per week or treatment as usual (TAU) control condition. Baseline and follow-up (6 weeks after the baseline assessment) assessments include clinical diagnostic and symptom assessment, standard neuropsychological testing, and structural and functional imaging.

The already recruited part of the ROP sample counts 27 participants in SCT and 27 in the TAU arm. The power analysis recommends to recruit at least 6 more participants in both study arms.

For the purpose of machine learning part of the analysis an independent psychosis (ROP)-healthy population (HC) classifier will be used, which takes the data from the naturalistic multi-center european study, Personalized Prognostic Tools for Early Psychosis Management, in order to be able to track the decision scores of the intervention SCT sample without risk of overfitting.

Study Overview

Status

Unknown

Conditions

Study Type

Interventional

Enrollment (Anticipated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Deutschland
      • München, Deutschland, Germany, 80336

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 40 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Language skills sufficient for participation
  • Sufficient capacity to consent
  • Presence of Psychotic Syndrome (POPS) based on the Structured Interview for Prodromal Syndromes (any of the Scale of Prodromal Symptoms (SOPS) rated with a 6 + symptoms occurring daily for more than one week AND any of the SOPS scales scored 6 + symptoms seriously disorganizing or dangerous)

Exclusion Criteria:

  • Intelligence Quotient (IQ) below 70
  • insufficient hearing for neuro-cognitive testing
  • current or past head trauma with loss of consciousness > 5 minutes
  • current or past known neurological disorder of the brain
  • current or past known somatic disorder potentially affecting the structure or functioning of the brain
  • current or past alcohol dependency according to Diagnostic and Statistic Manual (DSM-IV)
  • polytoxicomania within the past six months
  • inability to collect MRI data
  • antipsychotic medication for more than 90 cumulative days at or above the minimum dosage allowed based on guidelines set by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Social Cognitive Training (SCT)
10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week

SocialVille exercises in this study include 4 exercises:

  • Recognition: a speeded face matching task
  • Face to Face: a speeded facial emotion matching task
  • Gaze Match: a speeded gaze matching task
  • Face Poke: a continuous performance task with facial expressions
No Intervention: Treatment as usual (TAU)
This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global cognition
Time Frame: 6 weeks
An average of all cognitive domains (social cognition: [DANVA], speed of processing: [TMT-A, VFS, DSST], working memory: [Digit Span tests (Forward and Backward)], verbal learning: [RAVLT immediate recall], Attention: [CPT-IP], executive functioning: [TMT-B, VFP]) will be done to calculate the z-score transformed (from -4 to 4) global cognition score. The change will be made between endpoint and baseline.
6 weeks
Neural effects- Blood Oxygenation Level Dependent (BOLD) images
Time Frame: 6 weeks
Changes in strength of BOLD images-resting state functional connectivity in the seeds medial prefrontal cortex (mPFC) and amygdala between baseline and follow-up testing. BOLD time series will first be extracted from a 10-millimeter (mm)-radius sphere centered at the coordinates (-1, 47, -4, Montreal Neurological Institute-MNI) for the mPFC. Similarly, BOLD time series will also be extracted for the amygdala, using a 6-mm-radius sphere centered at (-20, -5, -9). Using the Resting-State Data Analysis Toolkit, a correlation map will be produced by computing the Pearson correlation coefficients between the average time course that is extracted for each seed (mPFC and amygdala) and each voxel in the whole brain for every participant. Correlation coefficients will be then converted to z-values using Fisher's r-to-z transform to improve normality and allow for parametric testing. Higher correlational coefficients correspond to higher resting state functional connectivity.
6 weeks
Decision scores of the ROP-HC classifier
Time Frame: 6 weeks
A linear Support Vector Machine (SVM) algorithm was used to develop an independent model distinguishing healthy control (HC) and recent-onset psychosis (ROP) participants based on resting-state functional connectivity (rsFC). This model will be built to identify disorder-related brain rsFC signatures and depict a spectrum of "HC-likeness" to "ROP-likeness" based on this neuroimaging modality. To measure changes in disorder-related brain signatures as a result of SCT, the HC-ROP classifier will be applied using out-of-sample-cross-validation (OOCV) to the ROP patients in the training study sample. This would allow us to determine whether decision scores of patients who received SCT were more likely to shift across the SVM hyperplane according to their rsFC pattern in a particular direction (ranging from -1.5 to 1.5). Patients in the SCT condition were expected to show greater shifts in the "HC-like" direction (-negative) as opposite to "ROP-like" (+positive).
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global functioning - Social (GF-S) and Role (GF-R)
Time Frame: 6 weeks
This scale separates social and role functioning in early psychosis spectrum. The scale is rated from 0-10, the social scale assesses aspects of social functioning such as, peer relationships and conflicts, involvement with family and age appropriate intimate relationships. The role scale assesses aspects of role functioning including type of age appropriate role (school/work/homemaking), quality of role. Higher scores represent higher functioning.
6 weeks
Global Assessment of Functioning (GAF)
Time Frame: 6 weeks

The Global Assessment of Functioning (GAF) is is used to rate symptoms and disability, ranging from the highest of a 100 (extremely high functioning) to the lowest rating 1 (severely impaired). An example of the scoring criterion can be as follows

- 100 to 91: Superior functioning with no symptoms that impair functioning and 10 to 1: A person is in almost constant danger of hurting themselves or others, has made a serious suicidal act with clear expectation of death, or both (https://www. healthline.com/health/gaf-score/). It is also rated on 3 time points, namely: in lifetime, past year and past month.

6 weeks
Positive and Negative Syndrome Scale (PANSS)
Time Frame: 6 weeks
The PANSS consists of 30 items meant to gauge the Positive, Negative, and General Psychopathology scales, each rated from 1-7. Higher values indicate higher rate of psychopathology whereas lower values indicate lower rates of psychopathology.
6 weeks
Cognitive Domain - Social Cognition (SC)
Time Frame: 6 weeks
The Diagnostic Analysis of Nonverbal Accuracy (DANVA) is a test of social cognition measuring the ability to read nonverbal social information. Scores range from 0 to 24 correct responses and were z-score transformed based on the study sample. Higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).
6 weeks
Cognitive Domain - Speed of Processing (SoP)
Time Frame: 6 weeks

Speed of processing was based on 3 neurocognitive tests:

  1. Trail Making Test: Part A (TMT-A)- A test of visual scanning and visuo- motor tracking (time to completion in milliseconds).
  2. Verbal Fluency: semantic (VFS)- A verbal index of speed of processing. The task is to recite as many words that belong to a particular category (animals) within 60 seconds (# of correct words).
  3. Wechsler Adult Intelligence Scale, 3rd ed., digit symbol coding task (DSST) - A measure of visuomotor speed within 90 seconds (# correct - maximum 90 items).

The three scores were z-score transformed based on the study sample and then combined (DSST - TMT-A + VFS). We subtract TMT-A because higher values represent worse performance in this measure, whereas VFS and DSST have higher scores representing better performance. For the z-score transformed scores that we will use higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).

6 weeks
Cognitive Domain - Working Memory (WM)
Time Frame: 6 weeks
Wechsler Memory Scale, 3rd ed., digit span subtest (DS) - A measure of nonverbal working memory (sum of # correct forward and backwards - maximum 15). These scores were z-score transformed based on the study sample. Higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).
6 weeks
Cognitive Domain - Verbal Learning (VL)
Time Frame: 6 weeks
Rey Auditory Verbal Learning Test (RAVLT) - A list of 15 words presented 5 times, which must be recalled from memory (total sum of correctly recalled words across 5 repetitions - maximum 75). These scores were z-score transformed based on the study sample. Higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).
6 weeks
Cognitive Domain - Attention (Attn)
Time Frame: 6 weeks
Continuous Performance Task - Identical Pairs (CPT-IP) - A measure of attention and vigilance using the signal detection index (d' = hits - false alarms). These scores were also z-score transformed based on the study sample. Higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).
6 weeks
Cognitive Domain - Executive Functioning (EF)
Time Frame: 6 weeks
Trail Making Test: Part B (TMT-B) - A test measuring cognitive flexibility and set shifting ability, connecting circles with a line alternating between letters and numbers (time to completion in milliseconds). Verbal Fluency: phonetic (VFP) - A verbal index of executive ability (# correct words). The two scores were z-score transformed based on the study sample and then combined (VFP - TMT-B). We subtract TMT-B because higher values represent worse performance in this measure. Higher z-scores stand for better performance and lower z-scores stand for worse performance (min -4.0, max +4.0).
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Anticipated)

February 29, 2020

Study Completion (Anticipated)

February 29, 2020

Study Registration Dates

First Submitted

May 15, 2019

First Submitted That Met QC Criteria

May 21, 2019

First Posted (Actual)

May 24, 2019

Study Record Updates

Last Update Posted (Actual)

January 10, 2020

Last Update Submitted That Met QC Criteria

January 8, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 972_961_PNKT_LKI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Data will be made available on request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychosis

Clinical Trials on SocialVille Social Cognitive Training

3
Subscribe